Decrease in Nitric Oxide Production as a Key Mediator in the Pathogenesis of Preeclampsia and a Potential Therapeutic Target: A Case-Control Study.
NO
gestational hypertension
hypertensive pregnancy
nitric oxide
preeclampsia
pregnancy complications
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
20 Oct 2022
20 Oct 2022
Historique:
received:
15
09
2022
revised:
13
10
2022
accepted:
18
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Pregnancy-induced hypertension (GH) complicates 6−10% of all pregnancies and, in 2019, was responsible for approximately 28,000 deaths. The most common cause of gestational hypertension is pre-eclampsia (PE), which afflicts 2−8% of all pregnancies and is one of the three leading causes of maternal morbidity and mortality worldwide. The aim of this study was to clarify how NO metabolism changes during the course of PE. Due to the short half-life of NO, we measured the concentrations of its stable metabolites, nitrite and nitrate (NOx). Out of 100 enrolled patients: 58 pregnant women with a diagnosed early form of PE formed a study group, and 42 healthy pregnant women formed a control group. NOx concentrations were significantly lower in the PE group than in the control group, with mean values of 5.33 and 27.64 μmol/L, respectively (p < 0.0001). The decrease in NO is most likely the result and mediator of systemic endothelial dysfunction. The impairment of NO metabolism in PE appears to play an important role in its pathogenesis. Therefore, it is a potential therapeutic target.
Identifiants
pubmed: 36289915
pii: biomedicines10102653
doi: 10.3390/biomedicines10102653
pmc: PMC9599382
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Gynecol Obstet Invest. 1999;48(2):93-7
pubmed: 10460998
Cell Adh Migr. 2016 Mar 3;10(1-2):154-62
pubmed: 26418186
Int J Mol Sci. 2021 Jan 12;22(2):
pubmed: 33445783
Semin Perinatol. 2012 Feb;36(1):56-9
pubmed: 22280867
Gynecol Obstet Invest. 1996;41(3):189-93
pubmed: 8698264
Am J Obstet Gynecol. 1994 Oct;171(4):944-8
pubmed: 7943106
J Matern Fetal Neonatal Med. 2016;29(16):2617-20
pubmed: 26456672
Hormones (Athens). 2015 Apr-Jun;14(2):211-23
pubmed: 26158653
Med Glas (Zenica). 2017 Aug 1;14(2):211-217
pubmed: 28786966
J Ultrasound Med. 2002 Aug;21(8):831-6
pubmed: 12164565
Br J Obstet Gynaecol. 1997 May;104(5):538-43
pubmed: 9166193
Adv Pharmacol. 2016;77:361-431
pubmed: 27451103
N Engl J Med. 2017 Aug 17;377(7):613-622
pubmed: 28657417
Curr Opin Obstet Gynecol. 2012 Dec;24(6):361-7
pubmed: 23108288
Hypertens Pregnancy. 2016 May;35(2):226-33
pubmed: 27003519
Ann Clin Lab Sci. 2002 Summer;32(3):257-63
pubmed: 12175088
Cells. 2020 Jul 08;9(7):
pubmed: 32650532
Am J Obstet Gynecol. 1993 Nov;169(5):1316-20
pubmed: 8238200
Sci Rep. 2021 Apr 29;11(1):9240
pubmed: 33927270
J Clin Hypertens (Greenwich). 2001 Mar-Apr;3(2):75-88
pubmed: 11416689
Int J Gynaecol Obstet. 2000 Mar;68(3):207-14
pubmed: 10699190
Circ Res. 2001 Jun 8;88(11):1210-5
pubmed: 11397789
Am J Physiol Renal Physiol. 2001 Apr;280(4):F592-8
pubmed: 11249850
J Clin Diagn Res. 2017 Jul;11(7):QC13-QC17
pubmed: 28892981
J Reprod Immunol. 2019 Sep;134-135:1-10
pubmed: 31301487
Am J Obstet Gynecol. 2007 Aug;197(2):e6-7
pubmed: 17689619
Adv Exp Med Biol. 2017;956:355-374
pubmed: 27873232
Epidemiology. 2003 May;14(3):368-74
pubmed: 12859040
Eur J Pharmacol. 2018 Mar 5;822:119-127
pubmed: 29355552